Coya Therapeutics, Inc. Common Stock (COYA) - Total Assets
Based on the latest financial reports, Coya Therapeutics, Inc. Common Stock (COYA) holds total assets worth $47.31 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Coya Therapeutics, Inc. Common Stock - Total Assets Trend (2020–2025)
This chart illustrates how Coya Therapeutics, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. Also see market value of Coya Therapeutics, Inc. Common Stock for the company's overall valuation and market capitalisation.
Coya Therapeutics, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
Coya Therapeutics, Inc. Common Stock's total assets of $47.31 Billion consist of 100.0% current assets and 0.0% non-current assets. Review COYA total debt and obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 93.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how Coya Therapeutics, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See COYA share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Coya Therapeutics, Inc. Common Stock's current assets represent 100.0% of total assets in 2025, a decrease from 100.0% in 2020.
- Cash Position: Cash and equivalents constituted 93.7% of total assets in 2025, down from 99.7% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Coya Therapeutics, Inc. Common Stock Competitors by Total Assets
Key competitors of Coya Therapeutics, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Coya Therapeutics, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.40 | 7.43 | 3.99 |
| Quick Ratio | 13.40 | 7.43 | 3.99 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $43.55 Billion | $28.93 Million | $3.44 Million |
Coya Therapeutics, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Coya Therapeutics, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.21 |
| Latest Market Cap to Assets Ratio | 2.19 |
| Asset Growth Rate (YoY) | 12.6% |
| Total Assets | $49.95 Million |
| Market Capitalization | $109.55 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Coya Therapeutics, Inc. Common Stock's assets at a significant premium (2.19x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Coya Therapeutics, Inc. Common Stock's assets grew by 12.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Coya Therapeutics, Inc. Common Stock (2020–2025)
The table below shows the annual total assets of Coya Therapeutics, Inc. Common Stock from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $49.95 Million | +12.63% |
| 2024-12-31 | $44.35 Million | +7.48% |
| 2023-12-31 | $41.26 Million | +391.48% |
| 2022-12-31 | $8.40 Million | +75.20% |
| 2021-12-31 | $4.79 Million | -45.23% |
| 2020-12-31 | $8.75 Million | -- |
About Coya Therapeutics, Inc. Common Stock
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneou… Read more